From locus to gene: causal inference and experimental validation prioritize PSMA4 as a candidate target in lung
Hui Lu1, Sai Wang1, Yuhang Ma1
1Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University Hefei, Anhui, China.
Abstract:
Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality worldwide, and although targeted therapy and immunotherapy have improved clinical outcomes, their long-term efficacy is frequently limited by therapeutic resistance, underscoring the need to identify additional biologically relevant and potentially actionable targets. In this study, we applied summary-data-based Mendelian randomization (SMR) by integrating lung cancer genome-wide association study (GWAS) summary statistics with cis-expression quantitative trait locus (cis-eQTL) and cis-methylation quantitative trait locus (cis-mQTL) datasets to prioritize candidate genes associated with LUAD risk. The robustness of SMR-significant signals was further evaluated using the heterogeneity in dependent instruments (HEIDI) test and Bayesian colocalization analysis. Independent transcriptomic datasets from the Gene Expression Omnibus (GEO), together with multiple public databases, were used for expression and prognostic validation, while protein-protein interaction (PPI) and functional enrichment analyses were performed to provide mechanistic context. Among 13 genes prioritized by integrative genetic analyses, PSMA4 (Proteasome 20S Subunit Alpha 4) emerged as the leading LUAD-relevant candidate on the basis of convergent multi-omics evidence, colocalization support, reproducible overexpression (OE) across independent cohorts, and adverse prognostic association. Functional experiments demonstrated that PSMA4 knockdown (KD) suppressed LUAD cell proliferation, migration, invasion, and xenograft tumor growth, whereas PSMA4 overexpression produced the opposite effects. Mechanistically, PSMA4 interacted with p53 and facilitated the proteasome-dependent turnover of ubiquitinated p53, as supported by co-immunoprecipitation, immunofluorescence, ubiquitination, proteasome inhibition, and cycloheximide chase assays, thereby attenuating p53 signaling. Collectively, these findings support PSMA4 as a biologically relevant and potentially actionable target in LUAD and provide a mechanistic rationale for further translational investigation.
Insights
This study identifies PSMA4 as a key target in lung adenocarcinoma (LUAD) by integrating genetic and multi-omics data. PSMA4 knockdown inhibits LUAD progression, offering a potential new therapeutic strategy for this deadly cancer.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Lung adenocarcinoma (LUAD) causes significant cancer mortality globally.
- Therapeutic resistance limits current targeted therapy and immunotherapy efficacy in LUAD.
- Identifying novel, actionable targets is crucial for improving LUAD patient outcomes.
Purpose of the Study:
- To prioritize candidate genes associated with LUAD risk using integrative genetic analyses.
- To identify and validate novel therapeutic targets for lung adenocarcinoma.
- To elucidate the functional role and mechanism of candidate genes in LUAD progression.
Main Methods:
- Summary-data-based Mendelian randomization (SMR) integrated GWAS, cis-eQTL, and cis-mQTL data.
- HEIDI and Bayesian colocalization analyses assessed SMR signal robustness.
- Independent transcriptomic data, GEO datasets, PPI, and functional enrichment analyses validated candidate genes.
Main Results:
- PSMA4 (Proteasome 20S Subunit Alpha 4) was prioritized as a leading LUAD-relevant gene.
- PSMA4 overexpression correlated with adverse prognosis; knockdown suppressed LUAD cell proliferation, migration, invasion, and tumor growth.
- PSMA4 facilitates p53 degradation via the proteasome, attenuating p53 signaling.
Conclusions:
- PSMA4 is a biologically relevant and potentially actionable therapeutic target in lung adenocarcinoma.
- PSMA4 promotes LUAD progression by destabilizing p53.
- These findings provide a mechanistic basis for PSMA4-targeted translational research in LUAD.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Abnormal Proliferation

